YUNNAN BAIYAO(SZ:000538)2026-01-27 09:06Group 1: Marketing Strategies - The Pharmaceutical Business Group focuses on becoming the "first brand" in pain management, leveraging the efficacy of Yunnan Baiyao products in this field [2] - Significant growth in aerosol and plaster products, with a comprehensive marketing strategy integrating various channels and scenarios [2][3] - Online sales increased by over 20%, with a total of 48.45 million visitors and 3.54 million consumers generated through e-commerce platforms, resulting in a GMV of 254 million yuan [3] Group 2: Dividend Distribution - For the 2024 fiscal year, the company will distribute a cash dividend of 11.85 yuan per 10 shares, totaling approximately 2.16 billion yuan, which is 90.09% of the net profit attributable to shareholders [4] - The total cash dividend for 2024, including special dividends, amounts to 23.98 yuan per 10 shares, with a total of 4.28 billion yuan [4][5] - In the first half of 2025, a cash dividend of 10.19 yuan per 10 shares will be distributed, totaling 1.82 billion yuan, representing 50.05% of the net profit for that period [5] Group 3: Future Product Development - The Health Products Business Group aims to be a leader in high-quality health products, focusing on oral care and expanding the product ecosystem [6] - Continuous enhancement of the oral product line and development of new products to strengthen market position [6] Group 4: R&D Planning - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative pharmaceuticals [7] - Ongoing projects include 16 major traditional Chinese medicine varieties and 37 development projects, with a focus on innovative drug development [8] - Short-term projects aim to enhance existing products, while long-term projects focus on innovative drug development aligned with social needs and technological advancements [8]